Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
The Philippine Department of Justice has found probable cause to indict officials from French drugmaker Sanofi and former and current Philippine health officials over 10 deaths the department said were linked to use of a dengue vaccine.
Merck & Co. Inc. said the combination of the drugmaker’s cancer immunotherapy Keytruda with Pfizer Inc.’s Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with the chemotherapy drug Sutent.
Researchers are reporting a link between doctor-targeted marketing of opioid products and the increase in U.S. deaths from overdoses.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.
A deadly viral outbreak claimed the life of a seventh child at a New Jersey rehabilitation center, where 11 other medically fragile young patients remain hospitalized with adenovirus infections, state health officials said.
International aid financing and innovation has helped to save nearly 700 million lives in the past 25 years, but those gains could be lost if momentum and political will wane, global health experts said.
Pfizer Inc.’s once-daily oral drug Vizimpro to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.
An estimated 6.3 million children died before their 15th birthdays in 2017 – or one every five seconds – mostly due to a lack of water, sanitation, nutrition and basic healthcare, according to report by United Nations agencies.